Evidence map›Paper›PMID 41150675›Full record

ArticlePloS one2025

Novel Linalool-Silver nanoparticles: Synthesis, characterization, and dual approach evaluation via computational docking and antibacterial assays.

Hina Manzoor, Mohammad A Alfhili, Shakeel Waqqar, Malik Arslan Ali, Faiza Hassan, Samiullah Khan, Muhammad Umer Khan

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hina ManzoorInstitute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.
Mohammad A AlfhiliDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
Shakeel WaqqarDepartment of Pathology and Laboratory Medicine, Auckland City Hospital, Auckland, New Zealand.
Malik Arslan AliInstitute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.
Faiza HassanChemistry Department, The University of Lahore, Lahore, Pakistan.
Samiullah KhanFaculty of Health and Life Sciences, INTI International University, Nilai, Negeri Sembilan, Malaysia.
Muhammad Umer KhanInstitute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.ORCID https://orcid.org/0000-0001-6289-5207

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, scientists have developed new medical delivery techniques based on nanotechnology and have been actively creating nanoparticles combined with various extracts from natural plant products. This study aimed to conjugate linalool surface with silver nanoparticles, investigate its characteristics, and evaluate its effectiveness as a possible new therapeutic target against bacterial strains. A CMC-linalool solution was used to create linalool-based AgNPs (LN@AgNPs), which were then characterized by UV-Vis, FTIR, SEM, DLS, and zeta potential studies. The shape, hydrodynamic diameter, and negative zeta potential were among the advantageous properties of the resultant particles, which improved their performance and stability. Antibacterial potential was assessed using both in silico and in vitro methods. According to molecular docking, LN@AgNPs exhibit strong interactions via hydrogen bonding and potential metallic chelation with important bacterial protein residues (Cys, His, and Thr). According to the in vitro assays, LN@AgNPs exhibited inhibitory zones comparable to those of azithromycin and stronger antibacterial efficacy than free linalool against Salmonella enterica, Bacillus subtilis, and Escherichia coli. According to these results, LN@AgNPs may be a good option for creating potent antimicrobial agents. To improve its therapeutic application, further investigation of its mode of action and in vivo safety profile is necessary.

Indexed as

Anti-Bacterial AgentsMetal NanoparticlesMonoterpenesSilverAcyclic MonoterpenesBacillus subtilisEscherichia coliMicrobial Sensitivity TestsMolecular Docking SimulationAcyclic MonoterpenesAnti-Bacterial AgentslinaloolMonoterpenesSilver

Identifiers

PMID41150675
PMCPMC12561953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.